| Raul Barroso, DO | |
|
2137 Lakeside Dr, Lynchburg, VA 24501-6806 | |
| (434) 404-7200 | |
| (434) 385-8616 |
| Full Name | Raul Barroso |
|---|---|
| Gender | Male |
| Speciality | Pediatrics |
| Location | 2137 Lakeside Dr, Lynchburg, Virginia |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1275681736 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | 0102206665 (Virginia) | Primary |
| Entity Name | Privia Medical Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013042480 PECOS PAC ID: 4385682061 Enrollment ID: O20140603000011 |
News Archive
"The sweeping health-care package unveiled this week by the White House appears to face big hurdles in the House, with abortion and unease among moderates potential stumbling blocks to winning passage of the legislation," The Wall Street Journal reports. President Obama's proposal Monday has "drawn mixed reviews from moderate Democrats," who face electoral pressures and in some cases dispute specific policy ideas. Sen. Ben Nelson, D-Neb., for instance, "criticized a new White House provision that would give the federal government powers to hold down insurance premiums, saying that should be up to the states" (Adamy and Hitt, 2/24).
PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced revenue guidance for the third quarter ended September 30, 2009 of approximately $71 million, as compared with $69 million for the third quarter of 2008. Royalty revenues are based on second quarter product sales by PDL's licensees and include $1.6 million for Synagis(R), which is marketed by MedImmune.
A recently identified immune cell that directs other cells to fight infection plays a critical role in regulating the immune system in both health and disease. Researchers from the University of Pennsylvania School of Medicine have discovered how a stimulatory molecule and a protein found on the membrane of another immune cell make T helper 17 cells multi-taskers of sorts. Th17 cells protect the body against infection and cancer, but are also culprits in some autoimmune diseases and out-of-control, cancerous cell growth.
Nektar Therapeutics today announced that the first subjects were dosed in a new Phase 1 clinical study to evaluate NKTR-181, the company's next-generation opioid analgesic candidate. NKTR-181 is being developed to effectively treat pain while addressing the abuse liability and serious CNS side effects associated with currently available opioid therapies.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Raul Barroso, DO 2137 Lakeside Dr, Lynchburg, VA 24501-6806 Ph: (434) 404-7200 | Raul Barroso, DO 2137 Lakeside Dr, Lynchburg, VA 24501-6806 Ph: (434) 404-7200 |
News Archive
"The sweeping health-care package unveiled this week by the White House appears to face big hurdles in the House, with abortion and unease among moderates potential stumbling blocks to winning passage of the legislation," The Wall Street Journal reports. President Obama's proposal Monday has "drawn mixed reviews from moderate Democrats," who face electoral pressures and in some cases dispute specific policy ideas. Sen. Ben Nelson, D-Neb., for instance, "criticized a new White House provision that would give the federal government powers to hold down insurance premiums, saying that should be up to the states" (Adamy and Hitt, 2/24).
PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced revenue guidance for the third quarter ended September 30, 2009 of approximately $71 million, as compared with $69 million for the third quarter of 2008. Royalty revenues are based on second quarter product sales by PDL's licensees and include $1.6 million for Synagis(R), which is marketed by MedImmune.
A recently identified immune cell that directs other cells to fight infection plays a critical role in regulating the immune system in both health and disease. Researchers from the University of Pennsylvania School of Medicine have discovered how a stimulatory molecule and a protein found on the membrane of another immune cell make T helper 17 cells multi-taskers of sorts. Th17 cells protect the body against infection and cancer, but are also culprits in some autoimmune diseases and out-of-control, cancerous cell growth.
Nektar Therapeutics today announced that the first subjects were dosed in a new Phase 1 clinical study to evaluate NKTR-181, the company's next-generation opioid analgesic candidate. NKTR-181 is being developed to effectively treat pain while addressing the abuse liability and serious CNS side effects associated with currently available opioid therapies.
› Verified 1 days ago
Morgan S Mandeville, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 105 Richeson Dr, Lynchburg, VA 24501 Phone: 434-385-7776 Fax: 434-385-5846 | |
John B Arnold, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 1212 Mcconville Road, Lynchburg, VA 24502 Phone: 434-237-8886 Fax: 434-239-6807 | |
Denise L Fenton, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 1212 Mcconville Road, Lynchburg, VA 24502 Phone: 434-237-8886 Fax: 434-239-6807 | |
Robert Skyler Mccurley, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 121 Mcconville Road, Lynchburg, VA 24502 Phone: 434-237-8886 Fax: 434-239-6807 | |
Dr. Richard C Morris, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 105 Richeson Dr, Lynchburg, VA 24501 Phone: 434-385-7776 Fax: 434-385-5846 | |
Bradley S Malcolm, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 105 Richeson Dr, Lynchburg, VA 24501 Phone: 434-385-7776 Fax: 434-385-5846 |